Step aside anti-coagulant meds, new device physically prevents strokes

Summary:A new device from Boston Scientific offers an alternative to stroke-preventing drugs. The mesh structure gets inserted into the heart cavity to physically prevent blood clots that cause strokes.

Scientists at Boston Scientific have developed a new heart implant for people at high risk for stroke.

More than 6 million people in the United States suffer from atrial fibrillation. Atrial fibrillation, the most common kind of irregular heartbeat, causes a third of all strokes.

Atrial fibrillation can lead to blood clots in the reservoir of the left atrium of the heart. These clots often block blood vessels, leading to a loss of blood supply to the brain -- an ischemic stroke.

Doctors typically prescribe atrial fibrillation patients with anti-coagulant drugs like Warfarin to prevent strokes. But these drugs come with risky potential side effects, most commonly hemorrhage or severe bleeding.

The new device, the WATCHMAN, offers an alternative to preventing clots pharmacologically.

Shown in a video in The Journal of Visual Experiments, doctors implant the umbrella-shaped nickel titanium net using a catheter. The device prevents blood clots from getting into trouble by trapping them in the reservoir of the left atrium of the heart. That's the area where 90% of clots arise.

The European Union, Australia and Latin America have already approved the WATCHMAN for medical use. The FDA permitted investigational use of the device in 2009, and Boston Scientific is currently running clinical trials to gain full commercial approval in the U.S.

Image: Journal of Visualized Experiments

This post was originally published on Smartplanet.com

Topics: Innovation

About

Audrey Quinn is a contributing writer.

Contact Disclosure

Kick off your day with ZDNet's daily email newsletter. It's the freshest tech news and opinion, served hot. Get it.

Related Stories

The best of ZDNet, delivered

You have been successfully signed up. To sign up for more newsletters or to manage your account, visit the Newsletter Subscription Center.
Subscription failed.